Thymic Cell Differentiation Media for Functional T Cell Maturation

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for generating thymic cells from pluripotent stem cells result in aberrant phenotypes and immature T cells, and lack efficient negative selection processes, hindering their therapeutic use in immune cell therapies.

Innovation Solution

Novel compositions and methods utilizing specific activators and inhibitors in cell culture media, such as Wnt, BMP, and Activin A, along with defined protein concentrations, to differentiate pluripotent stem cells into functional thymic cells, including thymic epithelial cells and progenitors, through staged differentiation protocols.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If current methods are used to generate T cells from pluripotent stem cells, then T cells can be produced, but the cells exhibit aberrant phenotypes and immaturity that prevent therapeutic use

Engineering Contradiction:
Improvecell differentiation qualityVSAvoidtherapeutic usability
Core Design Contradiction:
Manufacturing precisionVSReliability

Solution Approach 1:

The differentiation process is divided into distinct stages with specific media compositions for each stage: Stage 1 (days 0-3) uses media withActivin A and BMP4 to generate definitive endoderm; Stage 2 (days 3-7) uses media with Wnt activators and BMP inhibitors to generate foregut endoderm; Stage 3 (days 7-14) uses media with specific cytokines to generate thymic progenitors. This staged approach with precise media control at each step ensures proper cellular maturation and phenotype development, resolving the contradiction between production capability and therapeutic quality.

Inventive Principle:
Principle #1Segmentation

2Productivity

If pluripotent stem cells are differentiated using existing protocols, then cell production occurs, but negative selection of autoreactive T cells cannot be performed

Engineering Contradiction:
Improvecell production efficiencyVSAvoidnegative selection capability
Core Design Contradiction:
ProductivityVSAdaptability or versatility

Solution Approach 1:

The method performs preliminary actions by generating authentic thymic epithelial cells (TECs) and thymic progenitor cells (TEPs) with proper thymic architecture and function before T cell production. The staged differentiation protocol creates a functional thymic microenvironment that naturally performs negative selection during T cell education, enabling both high productivity and adaptive versatility for therapeutic applications.

Inventive Principle:
Principle #10Preliminary action

3Quantity of substance

If protein-enriched media is used for cell culture, then cell growth is supported, but differentiation efficiency into thymic cells decreases

Engineering Contradiction:
Improvecell viabilityVSAvoiddifferentiation efficiency
Core Design Contradiction:
Quantity of substanceVSManufacturing precision

Solution Approach 1:

The method dynamically adjusts media composition at each differentiation stage rather than using static protein-enriched media throughout. Stage 1 uses media with specific growth factors for endoderm formation, Stage 2 adjusts factors for foregut specification, and Stage 3 modifies composition for thymic progenitor generation. This dynamic media adjustment maintains cell viability while optimizing differentiation efficiency at each transition point.

Inventive Principle:
Principle #15Dynamics

Data Source

PatentUS20250382580A1Compositions and methods for accelerated production of thymic cells from pluripotent stem cells
Publication Date: 2025.12.18 THE REGENTS OF THE UNIVERSITY OF COLORADO
  • US20250382580A1 patent drawing
  • US20250382580A1 patent drawing
  • US20250382580A1 patent drawing

AI summary

Embodiments of the instant disclosure relate to novel compositions and methods for generating thymic cells. In some embodiments, thymic cells can be differentiated from pluripotent stem cells (PSC), anterior primitive streak (APS) cells, definitive endoderm (DE) cells, anterior foregut endoderm (AFE) cells, pharyngeal endoderm (PE) cells, ventral pharyngeal endoderm (VPE) cells, and third pharyngeal pouch endoderm (TPPE) cells using the compositions and methods disclosed herein. In certain embodiments, thymic cells generated by composition, systems and methods disclosed herein can be used to treat a health condition.